Revised Law Includes Designated Funding for Rare Diseases
Site Search
Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
As the Senate considers adding repeal of the Affordable Care Act's (ACA) individual mandate to its tax reform package, a group of 16 nonpartisan patient and consumer groups issued a statement on last week's Congressional Budget Office (CBO) report.
Un diagnóstico de fibrosis quística no debe descalificar a una persona para recibir atención que pueda salvarle la vida.
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.